# Immucell Corp: overview ICCC · Nasdaq · CIK 811641 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/iccc.md) · [Financials](/companies/iccc/financials.md) · [Filings](/companies/iccc/filings.md) · [Insiders](/companies/iccc/insiders.md) Latest reported revenue: [$7.2m](/filings/0001437749-26-027668.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027668). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.0](/filings/0001437749-25-034817.md) | [7.8 d](/filings/0001437749-26-010339.md) | [8.1](/filings/0001437749-26-017045.md) | [6.4](/filings/0001437749-26-027668.md) | [5.5](/filings/0001437749-25-034817.md) | [7.6 d](/filings/0001437749-26-010339.md) | [10.4](/filings/0001437749-26-017045.md) | [7.2](/filings/0001437749-26-027668.md) | | Gross margin | % | [26.3%](/filings/0001437749-25-034817.md) | [36.5% d](/filings/0001437749-26-010339.md) | [41.6%](/filings/0001437749-26-017045.md) | [43.7%](/filings/0001437749-26-027668.md) | [42.9%](/filings/0001437749-25-034817.md) | [38.2% d](/filings/0001437749-26-010339.md) | [45.0%](/filings/0001437749-26-017045.md) | [33.9%](/filings/0001437749-26-027668.md) | | Operating margin | % | [(9.6%)](/filings/0001437749-25-034817.md) | [8.0% d](/filings/0001437749-26-010339.md) | [13.9%](/filings/0001437749-26-017045.md) | [8.8%](/filings/0001437749-26-027668.md) | [0.4%](/filings/0001437749-25-034817.md) | [(0.8%) d](/filings/0001437749-26-010339.md) | [19.0%](/filings/0001437749-26-017045.md) | [26.9%](/filings/0001437749-26-027668.md) | | Net margin | % | [(11.7%)](/filings/0001437749-25-034817.md) | [6.6% d](/filings/0001437749-26-010339.md) | [17.9%](/filings/0001437749-26-017045.md) | [7.8%](/filings/0001437749-26-027668.md) | [(2.5%)](/filings/0001437749-25-034817.md) | [(37.4%) d](/filings/0001437749-26-010339.md) | [18.7%](/filings/0001437749-26-017045.md) | [25.5%](/filings/0001437749-26-027668.md) | | Diluted EPS | $ per share | [(0.09)](/filings/0001437749-25-034817.md) | not reported | [0.16](/filings/0001437749-26-017045.md) | [0.06](/filings/0001437749-26-027668.md) | [(0.02)](/filings/0001437749-25-034817.md) | not reported | [0.21](/filings/0001437749-26-017045.md) | [0.20](/filings/0001437749-26-027668.md) | | Free cash flow | $m | [(0.7) d](/filings/0001437749-25-034817.md) | [(0.2) d](/filings/0001437749-26-010339.md) | [1.2](/filings/0001437749-26-017045.md) | [1.4 d](/filings/0001437749-26-027668.md) | [(1.8) d](/filings/0001437749-25-034817.md) | [0.3 d](/filings/0001437749-26-010339.md) | [3.4](/filings/0001437749-26-017045.md) | [2.3 d](/filings/0001437749-26-027668.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [19.2](/filings/0001213900-23-086092.md) | [18.6](/filings/0001213900-24-028718.md) | [17.5](/filings/0001213900-24-028718.md) | [26.5](/filings/0001437749-26-010339.md) | [27.6](/filings/0001437749-26-010339.md) | | Gross margin | % | [45.0%](/filings/0001213900-23-086092.md) | [41.2%](/filings/0001213900-24-097450.md) | [22.1%](/filings/0001013762-25-004072.md) | [30.0%](/filings/0001437749-26-010339.md) | [41.4%](/filings/0001437749-26-010339.md) | | Operating margin | % | [1.3%](/filings/0001213900-23-086092.md) | [(12.4%)](/filings/0001213900-24-097450.md) | [(32.9%)](/filings/0001013762-25-004072.md) | [(6.2%)](/filings/0001437749-26-010339.md) | [6.0%](/filings/0001437749-26-010339.md) | | Net margin | % | [(0.4%)](/filings/0001213900-23-024080.md) | [(13.4%)](/filings/0001213900-24-028718.md) | [(33.1%)](/filings/0001013762-25-004072.md) | [(8.1%)](/filings/0001437749-26-010339.md) | [(3.8%)](/filings/0001437749-26-010339.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001213900-23-024080.md) | [(0.32)](/filings/0001213900-24-028718.md) | [(0.75)](/filings/0001013762-25-004072.md) | [(0.26)](/filings/0001437749-26-010339.md) | [(0.12)](/filings/0001437749-26-010339.md) | | Free cash flow | $m | [(1.7)](/filings/0001213900-23-024080.md) | [(5.5)](/filings/0001213900-24-028718.md) | [(6.6)](/filings/0001013762-25-004072.md) | [(0.1)](/filings/0001437749-26-010339.md) | [1.2](/filings/0001437749-26-010339.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iccc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.7m | 268,130 | | Added +7,803 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $2.4m | 233,910 | | Added +12,194 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.7m | 171,089 | | Added +19,300 | | [Cresset Asset Management, LLC](/funds/1761013.md) | 2026-06-30 | $1.4m | 135,267 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $726.5k | 72,270 | | Added +6,505 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $587.4k | 58,452 | | Added +2,422 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $502.5k | 50,000 | | Reduced −51,594 | | [Steadtrust LLC](/funds/2097595.md) | 2026-06-30 | $456.0k | 45,370 | | Reduced −9,000 | | [Mesirow Financial Investment Management, Inc.](/funds/1469475.md) | 2026-06-30 | $426.9k | 42,481 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $407.1k | 40,503 | | Added +4,807 | ## Recent filings [All 565 filings](/companies/iccc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 10:01 ET | [8-K](/filings/0001437749-26-032465.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-032465 | | 2026-08-13 | 20:08 ET | [10-Q](/filings/0001437749-26-027668.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027668 | | 2026-08-13 | 20:07 ET | [8-K](/filings/0001437749-26-027667.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027667 | | 2026-07-09 | 20:08 ET | [8-K](/filings/0001437749-26-023199.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-023199 | | 2026-06-17 | 18:19 ET | [8-K](/filings/0001437749-26-020926.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-020926 | | 2026-06-10 | 20:05 ET | [8-K](/filings/0001437749-26-020154.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-020154 | | 2026-05-14 | 20:09 ET | [8-K](/filings/0001437749-26-017049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-017049 | | 2026-05-14 | 20:07 ET | [10-Q](/filings/0001437749-26-017045.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017045 | | 2026-05-13 | 20:07 ET | [10-K/A](/filings/0001437749-26-016719.md) | Annual report, amended, period 2025-12-31 | 0001437749-26-016719 | | 2026-05-08 | 21:00 ET | [8-K](/filings/0001437749-26-015945.md) | 1.01 Entry into a material agreement | 0001437749-26-015945 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010339.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 811641 - Tickers: ICCC - Exchange: Nasdaq - SIC code: 2835 In Vitro & In Vivo Diagnostic Substances - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.